Testing

Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

In February 2019, Mayo Clinic Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

In January 2019, Mayo Clinic Laboratories announced three new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

The list of updates posted to mayocliniclabs.com during the month of January 2019 are now available.

Autoimmune neurological disorders can often be treated, sometimes with full restoration of function. However, because the symptoms mimic other conditions, autoimmune neurological disorders are frequently misdiagnosed, resulting in an irreversible loss of function.

numares and Mayo Clinic Laboratories have announced a collaboration to develop clinical diagnostic tests that will measure clusters of risk factors as opposed to individual biomarkers. The unique testing will use nuclear magnetic resonance technology, focusing on cardiovascular disease, kidney disease and liver cancer—among a few other specific diseases.

In close collaboration with our logistics providers, we have determined that clients can now safely send all specimens to Rochester now that temperatures have moderated. Thank you for your patience and understanding.

A movement disorder might be caused by the body’s immune system, which is meant to fight infections, suddenly attacking the brain. Fortunately, an “autoimmune movement disorder” can often be treated—once its cause is discovered.

In December 2018, Mayo Clinic Laboratories announced four new tests along with numerous reference value changes, obsolete tests, and algorithm changes. New Tests New tests[...]

In November 2018, Mayo Clinic Laboratories announced five new tests along with numerous reference value changes, obsolete tests, and algorithm changes.

In October 2018, Mayo Medical Laboratories announced one new test along with numerous reference value changes, obsolete tests, and algorithm changes.

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

Chromium and cobalt blood tests are used to monitor exposure to these elements. Both of these elements are naturally occurring and widely distributed in the environment. Previously, serum samples were collected and used to monitor patients with metal-on-metal implants, but serum can easily be contaminated during the harvesting and separation of the serum from the cellular blood components causing incorrect results. By using the new EDTA anticoagulated whole-blood test, which is collected in a trace element tube instead of using serum, the risk of contamination is significantly reduced.